Anticoagulation during extracorporeal membrane oxygenation

Troy Seelhammer; Jacob Ninan; Scott Nei; Christoph Gs Nabzdyk; Zhen Wang; Dana Gerberi; Patrick M Wieruszewski

doi:10.1002/14651858.CD015685

Anticoagulation during extracorporeal membrane oxygenation

Cochrane Database Syst Rev. 2024 Jun 10:6:CD015685. doi: 10.1002/14651858.CD015685.

Authors

Troy Seelhammer¹, Jacob Ninan², Scott Nei³, Christoph Gs Nabzdyk⁴, Zhen Wang⁵, Dana Gerberi⁶, Patrick M Wieruszewski^{1

3}

Affiliations

¹ Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
² Department of Nephrology and Critical Care, MultiCare Capital Medical Center, Olympia, WA, USA.
³ Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Critical Care and Anesthesia, Mass General Brigham, Boston, MA, USA.
⁵ Department of Health Services Research, Mayo Clinic, Rochester, MN, USA.
⁶ Mayo Medical Libraries, Mayo Clinic, Rochester, MN, USA.

PMID: 39804113
DOI: 10.1002/14651858.CD015685

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To determine the efficacy and safety of anticoagulation for maintaining extracorporeal membrane oxygenation in people of all ages with cardiac or respiratory failure, or both.

MeSH terms

Anticoagulants* / therapeutic use
Extracorporeal Membrane Oxygenation* / methods
Heart Failure / therapy
Heparin / therapeutic use
Humans
Randomized Controlled Trials as Topic
Respiratory Insufficiency* / therapy

Substances

Anticoagulants
Heparin